{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-075991","form_type":"8-K","ticker":null,"cik":"0001785345","company_name":"Landos Biopharma, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.524972+00:00","generated_at":"2026-06-04T08:34:29.348598+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AbbVie to acquire Landos Biopharma for $20.42/sh cash plus up to $11.14/sh CVR","bullets":["Total upfront cash consideration ~$137.5M; CVR milestone of up to $75M for Phase 3 start of NX-13 in UC by March 2029.","Landos stockholders holding ~57.6% of shares have agreed to vote in favor; deal expected to close Q2 2024.","NX-13 is a first-in-class oral NLRX1 agonist currently in Phase 2 NEXUS trial for moderate-to-severe ulcerative colitis.","CVRs are non-tradeable and contingent on initiating first Phase 3 trial for NX-13; no assurance milestone will be achieved.","Termination fee of $7M payable by Landos under certain circumstances if deal fails or a superior proposal accepted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-075991","json":"https://secwatch.observer/filing/0001193125-24-075991.json","markdown":"https://secwatch.observer/filing/0001193125-24-075991.md","text":"https://secwatch.observer/filing/0001193125-24-075991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/0001193125-24-075991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/d779916d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:34:29.348598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00c2a302dfd4d88b4ff685aa66c680221e00679d","claim":"Landos Biopharma, Inc. entered into Agreement and Plan of Merger with Bespin Subsidiary, LLC, Bespin Merger Sub, Inc., and AbbVie Inc. valued at $20.42 in cash per share plus one CVR representing $11.14 contingent cash per share (effective 2024-03-24).","evidence_excerpt":"On March 24, 2024, Landos Biopharma, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bespin Subsidiary, LLC, a Delaware corporation and a wholly owned Subsidiary of Guarantor (“Parent”), Bespin Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and solely for the limited purposes set forth therein, AbbVie Inc. (“AbbVie” or “Guarantor”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/0001193125-24-075991-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Bespin Subsidiary, LLC, Bespin Merger Sub, Inc., and AbbVie Inc."},{"label":"Value","value":"$20.42 in cash per share plus one CVR representing $11.14 contingent cash per share"},{"label":"Effective","value":"2024-03-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}